Fizazi, K., Mella, P. G., Castellano, D., Minatta, J. N., Kalebasty, A. R., Shaffer, D., … Pachynski, R. K. (2023). Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial. JOURNAL OF UROLOGY, 209(2), 445–446. https://doi.org/10.1097/JU.0000000000003046

Fizazi, K., P Gonzalez Mella, D. Castellano, J. N. Minatta, A. R. Kalebasty, D. Shaffer, JC Vazquez Limon, et al. “Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial.” JOURNAL OF UROLOGY 209, no. 2 (2023): 445–46. https://doi.org/10.1097/JU.0000000000003046.

Fizazi K, Mella PG, Castellano D, Minatta JN, Kalebasty AR, Shaffer D, et al. Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial. JOURNAL OF UROLOGY. 2023;209(2):445–6.

Fizazi, K., et al. “Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial.” JOURNAL OF UROLOGY, vol. 209, no. 2, 2023, pp. 445–46. Wos-lite, doi:10.1097/JU.0000000000003046.

Fizazi K, Mella PG, Castellano D, Minatta JN, Kalebasty AR, Shaffer D, Limon JCV, Lopez HMS, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK. Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial. JOURNAL OF UROLOGY. 2023;209(2):445–446.